scPharmaceuticals Inc is a progressive healthcare company focused on revolutionizing the way acute care and chronic care are delivered. The company believes in promoting patient-centric solutions that simplify and improve treatment for patients with cardiovascular and infectious diseases. scPharmaceuticals Inc takes pride in its commitment to delivering innovative and practical solutions that enhance patient outcomes. With a strong emphasis on research and development, the company is dedicated to advancing medical science and improving patient care. scPharmaceuticals Inc's corporate philosophy is rooted in accountability, integrity, and patient advocacy, ensuring a strong foundation for its continued growth and success.

scPharmaceuticals Inc is primarily present in the United States.

scPharmaceuticals Inc has achieved several significant milestones in its history. The company successfully developed and gained regulatory approval for its innovative subcutaneous formulation of furosemide, which enables the delivery of diuretic treatment to heart failure patients outside of the hospital setting. Additionally, scPharmaceuticals Inc initiated and completed a successful Phase III clinical trial for its lead product in acute and chronic heart failure patients. The company also secured multiple patents and expanded its product pipeline for the treatment of various conditions. These achievements demonstrate scPharmaceuticals Inc's commitment to developing novel therapies and improving patient care in the pharmaceutical industry.

scPharmaceuticals Inc is a pharmaceutical company that specializes in developing and commercializing transformative pharmaceutical products. Founded in [year], scPharmaceuticals aims to revolutionize the treatment of acute and chronic conditions through its innovative products. The company has a strong focus on delivering medications through the subcutaneous route, enhancing convenience and patient experience. With its cutting-edge technology and dedicated team, scPharmaceuticals has gained recognition and made significant advancements in the healthcare industry. As a leading player in the pharmaceutical sector, scPharmaceuticals Inc continues to strive towards improving patient outcomes and addressing unmet medical needs.

Some of the main competitors of scPharmaceuticals Inc in the market include Akebia Therapeutics, Correvio Pharma Corp, and NephroGenex.

scPharmaceuticals Inc is primarily active in the biopharmaceutical industry.

The business model of scPharmaceuticals Inc focuses on developing and commercializing innovative pharmaceutical products. The company aims to provide convenient and reliable alternative therapies for patients in need. By utilizing its proprietary technology, scPharmaceuticals Inc creates and delivers ready-to-use, subcutaneous medications. These products are designed to be self-administered by patients in various healthcare settings, including hospitals and homes. scPharmaceuticals Inc’s business model aims to improve patient experience and outcomes by providing effective and convenient treatment options.

Pašreizējais KGV scPharmaceuticals nevar tikt aprēķināts.

KUV šobrīd scPharmaceuticals nevar aprēķināt.

AlleAktien kvalitātes vērtējums scPharmaceuticals ir 3/10.

gaidāmā scPharmaceuticals apgrozījums ir 85,77 milj. USD.

gaidāmā scPharmaceuticals peļņa ir -49,52 milj. USD.

ScPharmaceuticals Inc is an American company that develops and markets drugs that can be used directly at the site of the patient's illness. This means that the drugs are not taken intravenously or orally as usual, but can be injected directly under the skin as a subcutaneous therapy (SC). The company has several divisions: The first includes drugs for the treatment of heart failure that can be injected directly at the site of the illness. The main product of this division is the Furoscix injection system, which is used to treat fluid accumulation in patients with acute heart failure. The system allows hospitals and other medical facilities to perform this important treatment on an outpatient basis. The second division of the company includes drugs for the treatment of highly acute migraines. These drugs are also injected directly at the site of the illness to achieve rapid effects when other medications do not work. Another product of the company is the infusion system, which is used for the treatment of patients in the hospital. This system allows for faster administration of medications and improves the treatment of critically ill patients. ScPharmaceuticals has also developed an innovative system that simplifies the administration of antibiotics in patients with cystic fibrosis. The typical antibiotics for the treatment of this condition are time-consuming and complex to use. ScPharmaceuticals has developed a system that makes them easier and faster, which is a great advantage for patients. The business model of ScPharmaceuticals focuses on the development and sale of medications that take place directly at the site of the illness, as well as the sale of accessories and related devices. By focusing on this niche, the company can develop innovative products and respond faster to the needs of patients. ScPharmaceuticals has an experienced management team and has close relationships with providers of medical devices and accessories. Through close collaboration with these partners, the company can quickly respond to new market developments. In summary, the business model of ScPharmaceuticals is based on the development of innovative drugs for the treatment of diseases at the site of the illness. The company specializes in a niche and focuses on collaborating with partners in the medical technology industry to be able to quickly respond to the needs of patients.

scPharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt scPharmaceuticals vai uzņēmums nedod dividendes.

scPharmaceuticals ISIN ir US8106481059.

scPharmaceuticals WKN ir A2H7XD.

scPharmaceuticals simbols ir SCPH.

Pēdējo 12 mēnešu laikā scPharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos scPharmaceuticals plāno maksāt dividendes 0 USD apmērā.

scPharmaceuticals pašreizējā dividendu rentabilitāte ir .

scPharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

scPharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

scPharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu scPharmaceuticals apmērā 0 USD, kas tika izmaksāta 20.01.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.01.2025..

Pēdējās dividendes izmaksa notika 20.01.2025..

Gadā 2024, scPharmaceuticals izmaksāja 0 USD dividendes.

scPharmaceuticals dividendes tiek izmaksātas USD.